CN103415518A - 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪 - Google Patents

在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪 Download PDF

Info

Publication number
CN103415518A
CN103415518A CN2011800677581A CN201180067758A CN103415518A CN 103415518 A CN103415518 A CN 103415518A CN 2011800677581 A CN2011800677581 A CN 2011800677581A CN 201180067758 A CN201180067758 A CN 201180067758A CN 103415518 A CN103415518 A CN 103415518A
Authority
CN
China
Prior art keywords
imidazo
pyrazin
cyclopropyl
amino
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800677581A
Other languages
English (en)
Chinese (zh)
Inventor
M·科皮茨
U·克拉尔
R·若泰拉特
D·科泽蒙德
R·博尔曼
B·巴德尔
P·利瑙
G·西迈斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN103415518A publication Critical patent/CN103415518A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2011800677581A 2010-12-17 2011-12-13 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪 Pending CN103415518A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10195702 2010-12-17
EP10195702.5 2010-12-17
PCT/EP2011/072583 WO2012080229A1 (en) 2010-12-17 2011-12-13 Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders

Publications (1)

Publication Number Publication Date
CN103415518A true CN103415518A (zh) 2013-11-27

Family

ID=45349508

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800677581A Pending CN103415518A (zh) 2010-12-17 2011-12-13 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪

Country Status (6)

Country Link
US (1) US20130303532A1 (https=)
EP (1) EP2651948A1 (https=)
JP (1) JP2014503521A (https=)
CN (1) CN103415518A (https=)
CA (1) CA2821829A1 (https=)
WO (1) WO2012080229A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115093416A (zh) * 2016-07-18 2022-09-23 大学健康网络 Ttk抑制剂的固体形式

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US9284317B2 (en) * 2010-12-17 2016-03-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
US9573954B2 (en) 2012-11-16 2017-02-21 University Health Network Pyrazolopyrimidine compounds
JP6095857B2 (ja) * 2013-11-15 2017-03-15 ユニバーシティ・ヘルス・ネットワーク ピラゾロピリミジン化合物
US9856258B2 (en) 2014-04-07 2018-01-02 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-E]indolizines
FI3283642T3 (fi) 2015-04-17 2024-01-11 Crossfire Oncology Holding B V Prognostisia biomarkkereita ttk-inhibiittorikemoterapiaan
KR102660894B1 (ko) * 2021-09-17 2024-04-26 기초과학연구원 피리미딘-2-아민 화합물의 제조방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009832A1 (en) * 2003-02-20 2005-01-13 Sugen, Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2008079460A2 (en) * 2006-09-05 2008-07-03 Emory University Tyrosine kinase inhibitors for prevention or treatment of infection
WO2009024824A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
CN101835780A (zh) * 2007-08-21 2010-09-15 生物焦点解析有限公司 用于治疗病毒感染诸如肝炎的咪唑并[1,2-a]吡嗪化合物
WO2010124826A1 (en) * 2009-04-29 2010-11-04 Bayer Schering Pharma Aktiengesellschaft Substituted imidazoquinoxalines
WO2011013729A1 (ja) * 2009-07-30 2011-02-03 オンコセラピー・サイエンス株式会社 Ｔｔｋ阻害作用を有する縮合イミダゾール誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
IL127566A0 (en) 1996-08-28 1999-10-28 Pfizer Substituted 6,5-hetero- bicyclic derivatives
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009832A1 (en) * 2003-02-20 2005-01-13 Sugen, Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2008079460A2 (en) * 2006-09-05 2008-07-03 Emory University Tyrosine kinase inhibitors for prevention or treatment of infection
CN101835780A (zh) * 2007-08-21 2010-09-15 生物焦点解析有限公司 用于治疗病毒感染诸如肝炎的咪唑并[1,2-a]吡嗪化合物
WO2009024824A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
WO2010124826A1 (en) * 2009-04-29 2010-11-04 Bayer Schering Pharma Aktiengesellschaft Substituted imidazoquinoxalines
WO2011013729A1 (ja) * 2009-07-30 2011-02-03 オンコセラピー・サイエンス株式会社 Ｔｔｋ阻害作用を有する縮合イミダゾール誘導体

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115093416A (zh) * 2016-07-18 2022-09-23 大学健康网络 Ttk抑制剂的固体形式
US11878980B2 (en) 2016-07-18 2024-01-23 University Health Network Solid forms of TTK inhibitor
CN115093416B (zh) * 2016-07-18 2024-04-12 大学健康网络 Ttk抑制剂的固体形式

Also Published As

Publication number Publication date
US20130303532A1 (en) 2013-11-14
EP2651948A1 (en) 2013-10-23
WO2012080229A1 (en) 2012-06-21
CA2821829A1 (en) 2012-06-21
JP2014503521A (ja) 2014-02-13

Similar Documents

Publication Publication Date Title
CN103443100B (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的取代的6-咪唑并吡嗪
CN102413831B (zh) 取代的咪唑并喹喔啉
CN102971321B (zh) 咪唑并吡嗪
CN102858768B (zh) 取代三唑并吡啶
JP5822944B2 (ja) 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン
CN103429592A (zh) 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪
CN103038235B (zh) 取代的咪唑并吡嗪
CN102596932A (zh) 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
WO2012080230A1 (en) 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP2014517053A (ja) ヘテロシクリルアミノイミダゾピリダジン
CN103415518A (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪
CN103403006B (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的6-硫代-取代的咪唑并吡嗪
CN104284896B (zh) 取代的咪唑并哒嗪
CN103649087B (zh) 取代的咪唑并吡啶及其中间体
HK1187622B (en) 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131127